Treatment(s) already received-Other Posts on Medivizor
Navigation Menu

Treatment(s) already received-Other Posts on Medivizor

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Posted by on Aug 21, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of testosterone replacement therapy (TRT) in men who had definitive treatment for prostate cancer. The authors concluded that TRT was not associated with a higher risk of recurrence in these patients. Some background Prostate cancer (PCa) is commonly fueled by the sex hormone testosterone....

Read More

Bone treatment for patients with multiple myeloma

Bone treatment for patients with multiple myeloma

Posted by on Nov 7, 2017 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the use of bone targeting agents in patients with multiple myeloma. The authors concluded that there could be insufficient bone targeted treatment in patients with multiple myeloma.  Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). This causes bone destruction, high...

Read More

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Can removal of the axillary lymph nodes be avoided if there is minimal involvement of the sentinel lymph nodes in breast cancer?

Posted by on Jun 29, 2013 in Breast cancer | 0 comments

In a nutshell This study tested the effect of complete axillary lymph node removal, on survival without recurrence of the cancer (called disease free survival or DFS) in patients with breast cancer.  Some background Lymph nodes are small organs which are part of the immune system. They filter fluid called lymph. Lymph can be thought of as the...

Read More

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Posted by on Mar 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This article presents the results of a phase II clinical trial that evaluated the efficacy and safety of the combination of two targeted therapies – cetuximab and erlotinib – for patients with metastatic colorectal cancer (mCRC). Some background Colorectal cancer that has spread outside the large...

Read More

Treating tumors of the appendix to reduce the risk of spread to the abdominal cavity

Posted by on Feb 26, 2013 in Colorectal cancer | 1 comment

In a nutshell The present study classified tumors of the appendix and reviewed treatments that aim to prevent cancer spread to the abdominal cavity. Some background Pseudomyxoma peritonei (PMP) is a rare condition caused by the production of too much mucin (a protein that is secreted in mucus).  PMP affects women more than men and symptoms...

Read More